Skip to content

Immunovant

US · IMVT #1790 by market cap Listed 2017
31.77 -0.75 -2.31%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 5 in the most recent period (2026/Q3).
  • Total institutional ownership rose 4.4 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
113.31% +4.38pp
Institutions
274 +5
As of
2026/Q3 vs. prior period

Holder types

Public Company58.87%
Mutual Fund30.32%
Hedge Fund15.23%
VC/PE Fund7.43%
Private Company1.05%
Individual/Insider0.71%
Insurance Company0.21%
Government Pension Fund0.16%

Top holders as of 2025-12-12

Roivant Sciences Ltd. 54.76% · 113.32M sh
FMR 7.58% · 15.69M sh
Deep Track Capital, LP 4.51% · 9.34M sh
BlackRock 3.59% · 7.43M sh
Farallon Capital Management, L.L.C. 2.81% · 5.81M sh
Morgan Stanley 2.75% · 5.68M sh
State Street Global Advisors 2.24% · 4.62M sh
Morgan Stanley Investment Management Inc. 2.75% · 5.68M sh
Baker Bros. Advisors LP 2.63% · 5.44M sh
Two Seas Capital LP 2.23% · 4.61M sh
T. Rowe Price Group, Inc. 1.96% · 4.05M sh
TCG Crossover Management, LLC 2.15% · 4.46M sh
Vanguard Capital Management, LLC 2.03% · 4.20M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 17 buys · 33 sells

NameRoleStake
Roivant Sciences Ltd. -- 54.76%
Peter Salzmann Former Chief Executive Officer 0.30%
William Macias Former CMO Emeritus 0.10%
Eva Barnett Former Chief Financial Officer 0.08%
Atul Pande Independent Director 0.05%
Michael Geffner Former Chief Medical Officer 0.04%
Douglas Hughes Independent Director 0.03%
Jay Stout Chief Technology Officer 0.02%
Christopher Van Tuyl Chief Legal Officer 0.02%
Tiago Girao Chief Financial Officer 0.02%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-10 Atul Pande Independent Director Derivative Exercise and Sale -3,000 $8.43–36.00
2026-10-27 Tiago Girao Chief Financial Officer Open Market Disposition -6,606 $28.50
2026-10-20 Jay Stout Chief Technology Officer Open Market Disposition -2,595 $28.94
2026-10-06 Christopher Van Tuyl Chief Legal Officer Open Market Disposition -1,327 $32.06
2026-10-06 Melanie Gloria Chief Operating Officer Open Market Disposition -2,241 $32.06
2026-10-06 Jay Stout Chief Technology Officer Open Market Disposition -3,809 $32.06
2026-10-01 Eric Venker Chief Executive Officer Derivative Exercise and Sale -89,392 $14.46–34.11
2026-09-30 Eric Venker Chief Executive Officer Derivative Exercise and Retained +2,795 $14.46
2026-09-22 Christopher Van Tuyl Chief Legal Officer Open Market Disposition -2,846 $36.36
2026-08-27 Atul Pande Independent Director Derivative Exercise and Sale -1,500 $8.43–43.27
2026-08-19 Melanie Gloria Chief Operating Officer Open Market Disposition -3,056 $44.16
2026-07-23 Atul Pande Independent Director Derivative Exercise and Sale -1,500 $8.43–39.80
2026-07-22 Tiago Girao Chief Financial Officer Open Market Disposition -6,798 $38.69
2026-07-22 Jay Stout Chief Technology Officer Open Market Disposition -2,857 $38.69
2026-07-07 Christopher Van Tuyl Chief Legal Officer Open Market Disposition -1,206 $39.53–39.99
2026-07-07 Melanie Gloria Chief Operating Officer Open Market Disposition -2,036 $39.53–39.99
2026-07-07 Jay Stout Chief Technology Officer Open Market Disposition -3,487 $39.53–39.99
2026-07-01 Eric Venker Chief Executive Officer Derivative Exercise and Sale -89,721 $14.46–38.48
2026-06-30 Eric Venker Chief Executive Officer Derivative Exercise and Retained +2,467 $14.46
2026-06-25 Atul Pande Independent Director Derivative Exercise and Sale -1,500 $8.43–38.01

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Immunovant discussion 0 comments

Add a comment